Information Provided By:
Fly News Breaks for July 28, 2015
MYL, AGN, TEVA
Jul 28, 2015 | 08:19 EDT
Bernstein increased its price target on Teva (TEVA) after the Israeli company agreed to buy Allergan's (AGN) generics business for $40.5B and dropped its proposal to acquire Mylan (MYL). The firm thinks the generics business can deliver about $8 of EPS to Teva by 2020, indicating that Teva is undervalued at current levels. Bernstein keeps an Outperform rating on Teva. It raised its price target on Allergan to $385 from $350 and keeps an Outperform rating on that stock.
News For TEVA;AGN;MYL From the Last 2 Days
TEVA
Apr 16, 2024 | 08:13 EDT
Teva Pharmaceuticals announced final results from the HD cohort of the Phase 4 START study, demonstrating positive real-world effectiveness, safety, adherence and satisfaction with the 4-week Titration Kit for AUSTEDO. As a fatal, neurodegenerative disease, HD can cause cognitive deterioration, behavioral and/or psychological problems and uncontrollable body movements known as chorea - a symptom that can have a significant impact on daily activities like eating or talking.3-5 These data are being presented at the 2024 American Academy of Neurology AAN Annual Meeting. "90% of HD patients experience chorea,3,4 so it's important for patients to have a treatment option that not only helps address symptoms, but helps provide a positive patient experience," said Eric Hughes, MD, PhD, Executive Vice President of Global R&D and Chief Medical Officer at Teva. "We remain committed to exploring ways to evolve the AUSTEDO treatment experience to meet the needs of the HD community, and these latest real-world data reinforce the role of the 4-week Titration Kit for AUSTEDO in empowering patients with HD chorea to find their optimal dose, adhere consistently to their treatment plan, and achieve effective outcomes."